For the quarter ending 2025-09-30, NTLA made $13,782,000 in revenue. -$100,987,000 in net income. Net profit margin of -732.75%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 13,782,000 | 14,245,000 | 16,627,000 | 16,255,333.333 |
| Research and development | 94,747,000 | 97,035,000 | 108,427,000 | 114,310,333.333 |
| General and administrative | 30,512,000 | 27,206,000 | 29,007,000 | 31,776,000 |
| Total operating expenses | 125,259,000 | 124,241,000 | 137,434,000 | 146,086,333.333 |
| Operating loss | -111,477,000 | -109,996,000 | -120,807,000 | -129,831,000 |
| Interest income | 6,714,000 | 7,402,000 | 8,603,000 | 11,895,000 |
| Change in fair value of investments, net | 3,439,000 | 1,339,000 | -2,125,000 | -9,833,666.667 |
| Total other income, net | 10,153,000 | 8,741,000 | 6,478,000 | 2,061,333.333 |
| Net loss | -101,324,000 | -101,255,000 | -114,329,000 | -127,769,666.667 |
| Unrealized gain on marketable securities | 337,000 | -404,000 | 452,000 | -1,240,333.333 |
| Comprehensive loss | -100,987,000 | -101,659,000 | -113,877,000 | -129,010,000 |
| Net loss per share, basic | -0.92 | -0.98 | -1.1 | -1.303 |
| Net loss per share, diluted | -0.92 | -0.98 | -1.1 | -1.303 |
| Weighted average shares outstanding, basic | 110,188,000 | 103,732,000 | 103,500,000 | -717,666.667 |
| Weighted average shares outstanding, diluted | 110,188,000 | 103,732,000 | 103,500,000 | -717,666.667 |
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)